Drug intelligence / Profile preview

FGR-001

Development stage: Unknown
Lead developer: ForagR Medicines
Modality: Small Molecules

Overview

FGR-001 is a preclinical-stage small molecule candidate developed by ForagR Medicines. It is discovered and developed using the company's proprietary RNA-centric, in-cell chemical genomics platform, which aims to identify small molecules that target and modulate RNA structures to regulate gene expression. FGR-001 serves as a representative asset demonstrating the platform's capability to modulate relative protein levels compared to vehicle controls. No specific molecular targets, therapeutic indications, or clinical development timelines have been publicly disclosed.

Beyond the preview

Go deeper on FGR-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FGR-001.

Explore the full profile